About Teva Pharmaceutical Industries Limited
https://www.tevapharm.comTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally.
CEO
Richard D. Francis
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2004-07-01 | Forward | 2:1 |
| 2002-12-06 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 268
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Goldman Sachs
Buy
B of A Securities
Buy
UBS
Buy
Piper Sandler
Overweight
JP Morgan
Overweight
Barclays
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:57.8M
Value:$1.89B
BLACKROCK INC.
Shares:42.99M
Value:$1.4B
PHOENIX HOLDINGS LTD.
Shares:41.3M
Value:$1.35B
Summary
Showing Top 3 of 828
About Teva Pharmaceutical Industries Limited
https://www.tevapharm.comTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $4.48B ▲ | $1.42B ▼ | $433M ▲ | 9.67% ▲ | $0.38 ▲ | $1.11B ▲ |
| Q2-2025 | $4.18B ▲ | $1.65B ▲ | $282M ▲ | 6.75% ▲ | $0.25 ▲ | $657M ▼ |
| Q1-2025 | $3.89B ▼ | $1.36B ▼ | $214M ▲ | 5.5% ▲ | $0.19 ▲ | $763M ▼ |
| Q4-2024 | $4.23B ▼ | $2.15B ▼ | $-217M ▲ | -5.13% ▲ | $-0.19 ▲ | $1.16B ▲ |
| Q3-2024 | $4.33B | $2.2B | $-437M | -10.09% | $-0.39 | $207M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.2B ▲ | $39.86B ▼ | $32.6B ▼ | $7.25B ▲ |
| Q2-2025 | $2.16B ▲ | $40.13B ▲ | $33.3B ▲ | $6.83B ▲ |
| Q1-2025 | $1.7B ▼ | $38.41B ▼ | $32.15B ▼ | $6.26B ▲ |
| Q4-2024 | $3.3B ▼ | $39.33B ▼ | $33.61B ▼ | $5.37B ▼ |
| Q3-2024 | $3.32B | $41.76B | $35.37B | $6.07B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $434M ▲ | $369M ▲ | $135M ▼ | $-453M ▼ | $42M ▼ | $233M ▲ |
| Q2-2025 | $282M ▲ | $227M ▲ | $236M ▲ | $6M ▲ | $464M ▲ | $131M ▲ |
| Q1-2025 | $214M ▲ | $-105M ▼ | $201M ▲ | $-1.74B ▼ | $-1.6B ▼ | $-232M ▼ |
| Q4-2024 | $-218.73M ▲ | $915M ▲ | $-138M ▼ | $-674M ▼ | $-19.01M ▼ | $786M ▲ |
| Q3-2024 | $-390M | $693M | $268M | $0 | $1.06B | $545M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Distribution Service | $800.00M ▲ | $380.00M ▼ | $380.00M ▲ | $410.00M ▲ |
 License | $90.00M ▲ | $40.00M ▼ | $50.00M ▲ | $50.00M ▲ |
 Product | $7.00Bn ▲ | $3.40Bn ▼ | $3.64Bn ▲ | $3.91Bn ▲ |
 Product and Service Other | $160.00M ▲ | $80.00M ▼ | $120.00M ▲ | $120.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Europe Segment | $2.63Bn ▲ | $1.19Bn ▼ | $1.30Bn ▲ | $1.24Bn ▼ |
 International Markets | $1.26Bn ▲ | $580.00M ▼ | $490.00M ▼ | $560.00M ▲ |
 North America Segment | $3.70Bn ▲ | $1.91Bn ▼ | $0 ▼ | $0 ▲ |
| United States Segment | $0 ▲ | $0 ▲ | $2.15Bn ▲ | $2.48Bn ▲ |
CEO
Richard D. Francis
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2004-07-01 | Forward | 2:1 |
| 2002-12-06 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 268
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Goldman Sachs
Buy
B of A Securities
Buy
UBS
Buy
Piper Sandler
Overweight
JP Morgan
Overweight
Barclays
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:57.8M
Value:$1.89B
BLACKROCK INC.
Shares:42.99M
Value:$1.4B
PHOENIX HOLDINGS LTD.
Shares:41.3M
Value:$1.35B
Summary
Showing Top 3 of 828